The phase number (http://en.wikipedia.org/wiki/Clinical_trial) refers to the highest clinical phase found in the broad literature.
Le numéro de phase (http://fr.wikipedia.org/wiki/Essai_clinique) se réfère à la phase clinique la plus élevée identifiée dans la littérature générale.
| | | | | | |
| Research Code | Species | Tradename | Target (antigen) | ||
| | | | | | |
| 17-1A | mouse | Panorex | 4 | CD326 (EpCAM) | |
| | | | | | |
| 7E11-C5.3 (CYT-351) | mouse | Prostascint | 4 | PSMA | |
| | | | | | |
| 88bv59 | human | HumaSPECT | 4 | Cytokeratin tumor-associated antigen | |
| | | | | | |
| ABX-EGF (E7,6,3) | human | Vectibix | 4 | EGFR | |
| | | | | | |
| B72.3 (CYT-099) | mouse | OncoScint | 4 | tumor-associated gp72 | |
| | | | | | |
| Campath-1H (LDP-03) | humanized | Campath MabCampath | 4 | CD52 | |
| | | | | | |
| CDP-771 (CMC-676, CMA-676) | humanized | MyloTarg | 4 | CD33 | |
| | | | | | |
| GSK-1841157 (HuMax-CD20 2F2) | human | Arzerra | 4 | CD20 | |
| | | | | | |
| IDEC-C2B8 (R-105 IDEC-102, RG-105) | chimeric | MabThera Rituxan | 4 | CD20 | |
| | | | | | |
| IDEC-In2B8 (IDEC-Y2B8 IDEC-129) | mouse | Zevalin | 4 | CD20 | |
| | | | | | |
| IMC-225 (IMC-C225) | chimeric | Erbitux | 4 | EGFR | |
| | | | | | |
| OC-125 | mouse | Inadmacis-125 | 4 | MUC16 (CA125) | |
| | | | | | |
| R-597 (4D5v8) | humanized | Herceptin | 4 | ErbB2 (HER2) | |
| | | | | | |
| SGN-35 (cAC10-vcMMAE) | chimeric | Adcetris | 4 | CD30 (TNFRSF8) | |
| | | | | | |
| TNFR-immunoadhesin | | Enbrel | 4 | TNFa | |
| | | | | | |
| | | Amevive | 4 | CD2 | |
| | | | | | |
| | rat/mouse hybrid | Removab | 4 | CD326 (EpCAM) + CD3E | |
| | | | | | |
| | mouse | Bexxar | 4 | CD20 | |
| | | | | | |
| IMMU-4Fab'-Tc99m | mouse | CEA-Scan | 4 | CEA | |
| | | | | | |
| | mouse | Verluma | 4 | gp40 carcinoma-associated antigen | |
| | | | | | |
| | mouse | Bexxar | 4 | CD20 | |
| | | | | | |
| ACA-125 (MEN-2234) | mouse | | 3 | MUC16 (CA125) | |
| | | | | | |
| AMG-412 (hLL2) | humanized | LymphoCide | 3 | CD22 | |
| | | | | | |
| AMG-479 | human | | 3 | CD221 (IGF1R) | |
| | | | | | |
| AVE0005 (VEGF Trap) | | | 3 | VEGF | |
| | | | | | |
| BEC2 | mouse | | 3 | CD3 ganglioside | |
| | | | | | |
| CNTO-328 (CLLB8) | chimeric | | 3 | IL6 | |
| | | | | | |
| CP-751871 | human | | 3 | CD221 (IGF1R) | |
| | | | | | |
| GA-101 (RO 5072759 huMAB<CD20> , afutuzumab) | humanized | | 3 | CD20 | |
| | | | | | |
| HuMax-EGFr (2F8) | human | | 3 | EGFR | |
| | | | | | |
| IMC-11F8 (11F8) | human | | 3 | EGFR | |
| | | | | | |
| IMMU-LL2 | mouse | LymphoScan | 3 | CD22 | |
| | | | | | |
| mAb-B43.13 (Oregovamab) | mouse | OvaRex | 3 | MUC16 (CA125) | |
| | | | | | |
| MORAb-003 (M3) | humanized | | 3 | FOLR1 (folate receptor alpha) | |
| | | | | | |
| PF-05208773 (WAY-207294 CMC-544) | humanized | | 3 | CD22 | |
| | | | | | |
| RG-1273 (RhuMAb-2C4) | humanized | OmniTarg | 3 | ErbB2 (HER2) | |
| | | | | | |
| RG-1549 (HMFG1, R-1549) | mouse | Theragyn | 3 | CD227 (MUC1) | |
| | | | | | |
| SGN-33 (Hum-195, Huma-195-gelonin) | humanized | Zamyl | 3 | CD33 | |
| | | | | | |
| SPECIFID (FavId) | mouse | | 3 | B-lymphoma cell | |
| | | | | | |
| T-DM1 | | | | 3 | ErbB2 (HER2) |
| | | | | | |
| TheraCIM-hR3 (hR3, Theraloc) | humanized | Theraloc Theracim | 3 | EGFR | |
| | | | | | |
| WX-G250 (CA9-SCAN cG250) | chimeric | Rencarex | 3 | Carbonic Anhydrase IX | |
| | | | | | |
| ABR-214936 | mouse | Anyara | 2 | TPBG (5T4 oncofetal antigen) | |
| | | | | | |
| ABR-217620 (Anyara, TTS CD3) | mouse | | 2 | TPBG (5T4 oncofetal antigen) | |
| | | | | | |
| AMG-102 | human | | 2 | HGF | |
| | | | | | |
| AMG-108 | | human | | 2 | IL1 system |
| | | | | | |
| AMG-145 | | | | 2 | PCSK9 |
| | | | | | |
| AMG-655 (TRAIL-R2mAb XG1-048) | human | | 2 | CD262 (DR5) | |
| | | | | | |
| Ch3G4 (Tarvacin) | chimeric | | 2 | phosphatidylserine | |
| | | | | | |
| CNTO-95 | human | | 2 | Integrin alpha5 | |
| | | | | | |
| CR-011-vcMMAE (CDX-011) | human | | 2 | GPNMB | |
| | | | | | |
| CT-011 | | | | 2 | PD-1 receptor |
| | | | | | |
| CYT-356 (90Y) | | mouse | Oncoltad | 2 | PSMA |
| | | | | | |
| EMD-273063 | | humanized | | 2 | Ganglioside GD2 |
| | | | | | |
| EMD-273066 (KSA-Interleukin-2, huKS-IL2) | humanized | | 2 | CD326 (EpCAM) | |
| | | | | | |
| EMD-72000 | humanized | | 2 | EGFR | |
| | | | | | |
| F16IL2 | | human | | 2 | Tenascin-C |
| | | | | | |
| hAFP-31 | humanized | AFP-Cide | 2 | AFP (alpha-fetoprotein) | |
| | | | | | |
| HGS-ETR1 (TRM-1) | human | | 2 | CD261 (DR4) | |
| | | | | | |
| hMN-14 | humanized | CEA-CIDE | 2 | CEA | |
| | | | | | |
| IMC-3G3 | human | | 2 | PDGFR-alpha | |
| | | | | | |
| IMC-A12 | human | | 2 | CD221 (IGF1R) | |
| | | | | | |
| IMGN-242 (huC242-DM4) | Cantuzumab Ravtansine | humanized | | 2 | MUC1 isoform (CanAg) |
| | | | | | |
| IMGN-901 (huN901-DM1, BB-10901) | humanized | | 2 | CD56 (NCAM) | |
| | | | | | |
| IMMU-106 (hA20) | humanized | | 2 | CD20 | |
| | | | | | |
| IMMU-107 (hPAM-DOTA hY-PAM4) | humanized | | 2 | CD227 (MUC1) | |
| | | | | | |
| IMMU-115 (hLL1) | humanized | | 2 | CD74 (MHC class II invariant chain) | |
| | | | | | |
| MDX-060 | human | | 2 | CD30 (TNFRSF8) | |
| | | | | | |
| MEDI-538 (MT-103, BITE MT-103,, bscCD19xCD3) | human | | 2 | CD19 + CD3E | |
| | | | | | |
| MK-0646 | humanized | | 2 | CD221 (IGF1R) | |
| | | | | | |
| MORAb-009 | chimeric | | 2 | Mesothelin | |
| | | | | | |
| MT-201 | human | | 2 | CD326 (EpCAM) | |
| | | | | | |
| PRO-95780 (anti-DR5 rhuMAb-DR5) | human | | 2 | CD262 (DR5) | |
| | | | | | |
| RAV-12 | | chimeric | | 2 | RAAG12 |
| | | | | | |
| SB-408075 (huC242-DM1) | humanized | | 2 | MUC1 isoform (CanAg) | |
| | | | | | |
| SCH-717454 (19D12) | human | | 2 | CD221 (IGF1R) | |
| | | | | | |
| SCH-900105 (AV-299) | humanized | | 2 | HGF | |
| | | | | | |
| SGN-40 (huS2C6) | humanized | | 2 | CD40 | |
| | | | | | |
| ST-2146 | mouse | | 2 | Tenascin C | |
| | | | | | |
| STX-100 | | humanized | | 2 | integrin alpha5-beta6 |
| | | | | | |
| TRA-8 (CS-1008) | humanized | | 2 | CD262 (DR5) | |
| | | | | | |
| | rat/mouse hybrid | Rexomun | 2 | ErbB2 (HER2) + CD3E | |
| | | | | | |
| AS-1402 (huHMFG-1) | humanized | | 1 | CD227 (MUC1) | |
| | | | | | |
| BIWA-1-DM1 | humanized | | 1 | CD44 | |
| | | | | | |
| CAT-8015 (HA-22) | mouse | | 1 | CD22 | |
| | | | | | |
| ETR2-ST01 (HGS-1018, HGS-ETR2) | human | | 1 | CD262 (DR5) | |
| | | | | | |
| HCD-122 (CHIR-12.12) | human | | 1 | CD40 | |
| | | | | | |
| HeFi-1 | | | | 1 | CD30 (TNFRSF8) |
| | | | | | |
| IMC-20D7S | human | | 1 | gp75 | |
| | | | | | |
| IMC-RON8 | human | | 1 | Ron receptor | |
| | | | | | |
| mAb-35 (ZCE-025) | mouse | Hybri-CEAker | 1 | CEA | |
| | | | | | |
| MLN-2704 (MLN-591DM1) | | humanized | | 1 | PSMA |
| | | | | | |
| NPC- | chimeric | | 1 | MUC5AC | |
| | | | | | |
| PDL-063 (huLuc63) | humanized | | 1 | CD319 (CS1) | |
| | | | | | |
| PDL-192 | humanized | | 1 | CD266 (TWEAKR) | |
| | | | | | |
| PF-04605412 | | | | 1 | Integrin - alpha5-beta1 |
| | | | | | |
| RG-3502 (Trastuzumab-MCC-DM1 T-DM1 PRO-132365) | humanized | | 1 | ErbB2 (HER2) | |
| | | | | | |
| RO-4858696 | human | | 1 | CD221 (IGF1R) | |
| | | | | | |
| VB4-845 | humanized | Proxinium Vicinium | 1 | CD326 (EpCAM) | |
| | | | | | |
| VB6-485 | humanized | | 1 | CD326 (EPCAM) | |
| | | | | | |
| VB6-845 | | humanized | | 1 | CD326 (EpCAM) |
| | | | | | |
| | mouse | | 1 | GM3 | |
| | | | | | |
| | chimeric | | 1 | EGFR (ErbB1, HER1) | |
| | | | | | |
| | human | | 1 | CD38 | |
| | | | | | |
| | mouse | | 1 | CD227 (MUC1) | |
| | | | | | |
| | mouse | | 1 | episialin | |
| | | | | | |
| BAY-86-5128 | mouse | | 1 | CD20 | |
| | | | | | |
| | mouse | | 1 | TAG-72 | |
| | | | | | |
| | mouse | | 1 | Colorectal tumor antigen C242 | |
| | | | | | |
| | mouse | | 1 | adenocarcinoma antigen | |
| | | | | | |
| | human | | 1 | Vimentin | |
| | | | | | |
| | humanized | | 1 | FAP | |
| | | | | | |
| | mouse | | 1 | CD19 | |
| | | | | | |
| PRO-143996 (MetMAb) | humanized | | | Scatter factor receptor (MET) | |
| | | | | | |
| | chimeric | | | Syndecan-1 | |
| | | | | | |
